Back to Search Start Over

Efficacy and safety of Optilume® paclitaxel-coated urethral dilatation balloon in real-life: experience in a Spanish multicenter study.

Authors :
Ballesteros Ruiz C
Campos-Juanatey F
Povo Martín I
Mitjana Biosca S
Gorría Cardesa Ó
Aguilar Guevara JF
García Formoso N
Fernández Pascual E
Martínez Salamanca JI
Martínez Pérez S
Alonso Dorrego JM
Ríos González E
San Cayetano Talegón S
Araujo Suarez AM
Moran Pascual E
Bonillo García MÁ
Medina Polo J
Viver Clotet L
Vicens Morton AJ
Arce Gil J
Sos Cambras L
Ibáñez Vázquez L
Hermida Gutiérrez J
Moncada Castro EM
Ponce de León Roca J
Torres León L
Martínez-Piñeiro Lorenzo L
Source :
Actas urologicas espanolas [Actas Urol Esp (Engl Ed)] 2024 Oct 30. Date of Electronic Publication: 2024 Oct 30.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Introduction: The Optilume® Paclitaxel-coated urethral dilatation balloon is an alternative to conventional endoscopic treatments that combines mechanical dilatation with local delivery of paclitaxel.<br />Objective: To describe the success rate and analyze the safety of the device in real clinical practice. To evaluate possible predictors of treatment failure.<br />Materials and Methods: Retrospective multicenter study in patients diagnosed with urethral stricture and treated with an Optilume® balloon in routine clinical practice. Data were collected from flowmetry, questionnaires (PROM and IPSS) and cystoscopy before surgery, and 3, 6 and 12 months after the procedure, according to standard practice. Surgical success was defined as the absence of subsequent urethral manipulation and a Qmax >10 ml/s.<br />Results: 238 patients treated with Optilume® in 12 Spanish hospitals between May 2021 and April 2024 were included in the study. Of these, 156 who had a minimum follow-up of 3 months, were analyzed. Median stricture length: 1.5 cm (0.5-5.3), mainly in bulbar urethra (87.7%). Of the total, 12.8% of patients had a history of pelvic radiotherapy, and 81.4% had undergone prior urethral manipulation. Postoperative complications were reported in 14.2% of the total. The treatment success rate was 73.8%, with a median follow-up of 8 months (5-12). No predictors of stricture recurrence were identified. Recurrence rates were higher in strictures located in the posterior versus anterior urethra (42.9% vs. 24.6%, p = 0.126). No significant differences were observed between patients with and without prior urethral manipulation.<br />Conclusion: Treatment with Optilume® has been shown to be safe and effective in short-term routine clinical practice.<br />Competing Interests: Declaration of competing interest None of the authors have any conflict of interest to declare in relation to the content of this article.<br /> (Copyright © 2024. Published by Elsevier España, S.L.U.)

Details

Language :
English; Spanish; Castilian
ISSN :
2173-5786
Database :
MEDLINE
Journal :
Actas urologicas espanolas
Publication Type :
Academic Journal
Accession number :
39486795
Full Text :
https://doi.org/10.1016/j.acuroe.2024.10.003